DOCSLIB.ORG

Susceptibility and Resistance Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

toku-e logo For a complete list of references, please visit antibiotics.toku-e.com Levofloxacin Microorganism Genus, Species, and Strain (if shown) Concentration Range (μg/ml)Susceptibility and Aeromonas spp. 0.0625 Minimum Inhibitory Alcaligenes faecalis 0.39 － 25 Bacillus circulans Concentration0.25 － 8 (MIC) Data Bacillus subtilis (ATCC 6051) 6.25 Issue date 01/06/2020 Bacteroides capillosus ≤0.06 － >8 Bacteroides distasonis 0.5 － 128 Bacteroides eggerthii 4 Bacteroides fragilis 0.5 － 128 Bacteroides merdae 0.25 － >32 Bacteroides ovatus 0.25 － 256 Bacteroides thetaiotaomicron 1 － 256 Bacteroides uniformis 4 － 128 Bacteroides ureolyticus ≤0.06 － >8 Bacteroides vulgatus 1 － 256 Bifidobacterium adolescentis 0.25 － >32 Bifidobacterium bifidum 8 Bifidobacterium breve 0.25 － 8 Bifidobacterium longum 0.25 － 8 Bifidobacterium pseudolongum 8 Bifidobacterium sp. 0.25 － >32 Bilophila wadsworthia 0.25 － 16 Brevibacterium spp. 0.12 － 8 Brucella melitensis 0.5 Burkholderia cepacia 0.25 － 512 Campylobacter coli 0.015 － 128 Campylobacter concisus ≤0.06 － >8 Campylobacter gracilis ≤0.06 － >8 Campylobacter jejuni 0.015 － 128 Campylobacter mucosalis ≤0.06 － >8 Campylobacter rectus ≤0.06 － >8 Campylobacter showae ≤0.06 － >8 Campylobacter spp. 0.25 Campylobacter sputorum ≤0.06 － >8 Capnocytophaga ochracea ≤0.06 － >8 Capnocytophaga spp. 0.006 － 2 Chlamydia pneumonia 0.125 － 1 Chlamydia psittaci 0.5 Chlamydia trachomatis 0.12 － 1 Chlamydophila pneumonia 0.5 Citrobacter diversus 0.015 － 0.125 Citrobacter freundii ≤0.00625 － >64 Citrobacter koseri 0.015 － >8 Citrobacter spp. 0.008 － 64 Clostridium baratii 0.5 － 4 Clostridium bifermentans 0.5 － 4 Clostridium cadaveris 0.12 － 16 Clostridium clostridioforme 16 Clostridium difficile 1 － 128 Clostridium hastiforme 0.5 － 4 Clostridium innocuum 0.12 － 16 Clostridium malenominatum 0.12 － 16 Clostridium oroticum 0.12 － 16 Clostridium paraputrificum (ATCC 25780) 1 Clostridium perfringens 0.12 － 32 Clostridium putrificum 0.25 Clostridium ramosum 0.5 － 8 Clostridium septicum 0.125 Clostridium sordellii 0.12 － 16 Clostridium sporogenes 0.12 － 16 Clostridium spp. 0.06 － 32 Clostridium tertium 0.5 － 4 Collinsella aerofaciens ≤0.06 － 2 Corynebacterium afermentans 0.12 － 8 Corynebacterium amycolatum 0.12 － 64 Corynebacterium jeikeium 0.12 － 16 Corynebacterium minutissimum 0.06 － 16 Corynebacterium pseudodiphtheriticum 0.25 － 16 Microorganism Genus, Species, and Strain (if shown) Concentration Range (μg/ml)Susceptibility and Corynebacterium spp. 0.125 － 64Minimum Inhibitory Corynebacterium striatum 0.12 － 64 Corynebacterium urealyticum 0.12 － >128 Coryneform 0.12 － 8 Desulfovibrio piger 0.125 Dialister pneumosintes ≤0.06 － >8 Eggerthella lenta 0.5 Eikenella corrodens ≤0.06 Enterobacter aerogenes ≤0.008 －64 Enterobacter agglomerans ≤0.25 － >8 Enterobacter cloacae ≤0.003 － 64 Enterobacter sakazakii ≤0.25 － 2 Enterobacter spp. <0.004 － 64 Enterobacteriaceae ≤0.008 － >16 Enterococci 0.5 － 50 Enterococcus avium 0.06 － >64 Enterococcus casseliflavus 0.06 － >4 Enterococcus durans 0.06 － >4 Enterococcus faecalis 0.006 － 9750 Enterococcus faecium 0.06 - >128 Enterococcus gallinarum 0.06 － 32 Enterococcus hirae 0.06 － >4 Enterococcus mundtii 0.06 － >4 Enterococcus raffinosus 0.06 － >4 Enterococcus spp. 0.06 － >4 Erysipelothrix rhusiopathiae 0.06 Erysipelothrix spp. 0.06 － 0.12 Escherichia coli ≤0.004 － >128 Eubacterium 0.12 － 4 Eubacterium lentum ≤0.06 － 2 Eubacterium limosum 0.12 － 4 Eubacterium nodatum 0.12 － 4 Eubacterium saburreum 0.25 － >8 Eubacterium spp. ≤0.06 － 8 Eubacterium timidum ≤0.06 － 2 Eubacterium yurii ≤0.06 － 2 Finegoldia magna 0.094 － 128 Fusobacteria 0.5 － >32 Fusobacterium ≤0.015 － 4 Fusobacterium mortiferum 0.5 － 1 Fusobacterium naviforme 0.25 － >8 Fusobacterium necrophorum 0.25 － >8 Fusobacterium nucleatum ≤0.03 － >32 Fusobacterium spp. 0.03 － >32 Fusobacterium varium 4 － >32 Gardnerella vaginalis 0.5 － >8 Gemella morbillorum 0.006 － 2 Gram-Positive Anaerobic Cocci 0.25 － 8 Haemophilus influenzae ≤0.004 － 16 Haemophilus parainfluenzae 0.006 － 2 Haemophilus spp. 0.32 - 16 Helicobacter pylori 0.008 － 250 Hemolytic streptococci 0.25 － 2 Hemophilus influenzae 0.016 － 0.031 Klebsiella ≤0.03 － >8 Klebsiella oxytoca 0.015 － 8 Klebsiella pneumonia <0.004 － 128 Klebsiella spp. 0.015 － 1 Lactobacillus acidophilus (JCM 1132) 32 Lactobacillus brevis (JCM 1059) 8 Lactobacillus casei (JCM 1134) 1 Lactobacillus catenaforme 0.25 － 8 Lactobacillus delbrueckii 0.25 － 8 Lactobacillus fermentum (JCM 1173) 8 Lactobacillus jensenii 0.12 － 4 Lactobacillus oris 0.25 － 8 Lactobacillus plantarum 0.25 － 8 Lactobacillus reuteri (JCM 1112) 16 Lactobacillus salivarius (JCM 1231) 1 Lactobacillus spp. 0.12 － 8 Legionella adelaidensis ≥0.008 Legionella anisa ≥0.032 Microorganism Genus, Species, and Strain (if shown) Concentration Range (μg/ml)Susceptibility and Legionella birminghamiensis ≥0.032 Minimum Inhibitory Legionella bozemanii ≥0.023 Legionella brunensis ≥0.032 Legionella cherrii ≥0.016 Legionella cincinnatiensis ≥0.016 Legionella dumofii ≥0.025 Legionella erythra ≥0.016 Legionella fairfieldensis ≥0.025 Legionella feeleii ≥0.04 Legionella geestiana ≥0.004 Legionella gormanii ≥0.023 Legionella gratiana ≥0.064 Legionella hackeliae ≥0.125 Legionella israelensis ≥0.016 Legionella jamestowniensis ≥0.032 Legionella jordanis ≥0.032 Legionella lansingensis 0.008 － 0.125 Legionella longbeachae ≥0.027 Legionella maceachernii ≥0.016 Legionella micdadei ≥0.018 Legionella moravica ≥0.008 Legionella nautarum ≥0.064 Legionella oakridgensis ≥0.016 Legionella pneumophila 0.002 － 0.5 Legionella quateirensis ≥0.008 Legionella quinlivanii ≥0.032 Legionella rubrilucens ≥0.016 Legionella sainthelensi ≥0.032 Legionella santicrucis ≥0.012 Legionella shakespearei ≥0.125 Legionella spiritensis ≥0.016 Legionella spp. 0.0039 － 0.06 Legionella steigerwaltii ≥0.024 Legionella tucsonensis ≥0.032 Legionella wadsworthii ≥0.008 Legionella worsleiensis ≥0.006 Leptotrichia buccalis 0.25 － >8 Leuconostoc spp. 1 － 2 Leuconostoc spp. <1000 Listeria monocytogenes 0.25 － 2 Listeria spp. 0.5 － 2 Micrococcus luteus (LB 14110) 200 Micromonas micros 0.125 － 0.5 Moraxella catarrhalis ≤0.006 － >4 Moraxella sp. 0.064 Morganella morganii 0.0125 － 64 Morganella spp. ≤0.25 － 64 Mycobacterium abscessus 1 － 64 Mycobacterium avium 0.5 － 64 Mycobacterium chelonae 0.25 － 64 Mycobacterium fortuitum ≤0.03 － 1 Mycobacterium intracellulare 16 － 25 Mycobacterium marinum 0.032 － 16 Mycobacterium mucogenicum 0.12 － 2 Mycobacterium peregrinum ≤0.03 － 0.25 Mycobacterium tuberculosis 0.0625 － 8 Mycoplasma fermentans ≤0.008 － 1 Mycoplasma genitalium 0.5 － 1 Mycoplasma hominis 0.016 － 2 Mycoplasma penetrans 0.06 － 0.25 Mycoplasma pneumonia 0.063 － 2 Neisseria cinerea 0.007 － 1 Neisseria elongata 0.008 － 1 Neisseria lactamica <0.003 － 0.015 Neisseria meningitidis ≤0.003 － 0.03 Neisseria mucosa 0.007 － 0.03 Neisseria perflava/sicca <0.003 － 0.12 Neisseria polysaccharea <0.003 Neisseria sicca 0.001 － 1 Nonsporing gram-positive rods 0.25 － 32 Oerskovia spp. 0.12 － 8 Olsenella uli 0.25 － 8 Microorganism Genus, Species, and Strain (if shown) Concentration Range (μg/ml)Susceptibility and Pantoea agglomerans 0.015 － 0.06Minimum Inhibitory Parvimonas micra 0.125 － 3 Pasteurella multocida <0.5 Pediococcus spp. 8 Peptoniphilus asaccharolyticus 4 － 128 Peptoniphilus gorbachii 3 － 64 Peptoniphilus harei 2 － 64 Peptoniphilus indolicus 4 Peptoniphilus ivorii 0.38 － 64 Peptoniphilus lacrimalis 3 － 8 Peptoniphilus octavius 4 Peptostreptococcus ≤0.015 － 16 Peptostreptococcus anaerobius 0.12 － 128 Peptostreptococcus asaccharolyticus 0.12 － 25 Peptostreptococcus magnus 0.12 － 16 Peptostreptococcus micros 0.12 － 16 Peptostreptococcus prevotii 0.12 － 16 Peptostreptococcus spp. 0.12 － 664 Peptostreptococcus tetradius 0.25 － 16 Plesiomonas shigelloides 0.0625 Pneumococci 0.5 － >32 Porphyromonas ≤0.015 － 16 Porphyromonas endodontalis ≤0.06 － >32 Porphyromonas gingivalis ≤0.06 － >8 Porphyromonas spp. 0.06 － 2 Prevotella bivia ≤0.03 － 16 Prevotella buccalis ≤0.06 － >8 Prevotella corporis 0.125 － 4 Prevotella dentalis ≤0.06 － >8 Prevotella denticola 0.125 － 16 Prevotella disiens ≤0.06 － 16 Prevotella heparinolytica 1 Prevotella intermedia ≤0.06 －16 Prevotella loescheii 0.125 － 16 Prevotella melaninogenica 0.125 － 16 Prevotella nigrescens ≤0.06 － >8 Prevotella oralis ≤0.06 －16 Prevotella oris ≤0.06 － 16 Prevotella pallens ≤0.06 － >8 Prevotella spp. ≤0.06 － 16 Prevotella tannerae 0.125 － 4 Prevotella zooglioformans ≤0.06 － >8 Propionibacteria 0.25 － 0.5 Propionibacterium 0.12 － 8 Propionibacterium avidum 0.25 － 8 Propionibacterium granulosum 0.25 Propionibacterium sp. 0.25 － >32 Proteus 0.03 － >128 Proteus mirabilis 0.015 － 12220 Proteus rettgeri ≤0.06 － >8 Proteus spp. 0.25 Proteus vulgaris 0.015 － 8 Providencia alcalifaciens 0.06 － >16 Providencia rettgeri 0.06 － >16 Providencia spp. ≤0.25 － 64 Providencia stuartii 0.06 － >16 Pseudomonas aeruginosa ≤0.008 － 256 Pseudomonas savastanoi ≥3.13 Pseudomonas syringae. pv. tomato ≥6.25 Rhodococcus equi 0.25 － 1 Rothia dentocariosa 0.006 － 2 Rothia mucilaginosa 0.006 － 2 Ruminococcus gnavus 64 Salmonella enterica <0.008 － 16 Salmonella enteritidis 0.00625 － 0.1 Salmonella spp. 0.015 － 2 Salmonella typhi <0.008 － 1220 Salmonella/Shigella spp. 0.015 － 0.06 Selenomonas flueggei ≤0.06 － >8 Selenomonas infelix ≤0.06 － >8 Selenomonas spp. ≤0.06 － >8 Serratia liquefaciens 0.015 － 1 Microorganism Genus, Species, and Strain (if shown) Concentration Range (μg/ml)Susceptibility and Serratia marcescens 0.015 － >128Minimum Inhibitory Serratia spp. ≤0.25 － 64 Shigella boydii 0.015 － 0.06
Recommended publications
  • NCTC) Bacterial Strain Equivalents to American Type Culture Collection (ATCC) Bacterial Strains

    NCTC) Bacterial Strain Equivalents to American Type Culture Collection (ATCC) Bacterial Strains

    This list shows National Collection of Type Cultures (NCTC) bacterial strain equivalents to American Type Culture Collection (ATCC) bacterial strains. NCTC Number CurrentName ATCC Number NCTC 7212 Acetobacter pasteurianus ATCC 23761 NCTC 10138 Acholeplasma axanthum ATCC 25176 NCTC 10171 Acholeplasma equifetale ATCC 29724 NCTC 10128 Acholeplasma granularum ATCC 19168 NCTC 10172 Acholeplasma hippikon ATCC 29725 NCTC 10116 Acholeplasma laidlawii ATCC 23206 NCTC 10134 Acholeplasma modicum ATCC 29102 NCTC 10188 Acholeplasma morum ATCC 33211 NCTC 10150 Acholeplasma oculi ATCC 27350 NCTC 10198 Acholeplasma parvum ATCC 29892 NCTC 8582 Achromobacter denitrificans ATCC 15173 NCTC 10309 Achromobacter metalcaligenes ATCC 17910 NCTC 10807 Achromobacter xylosoxidans subsp. xylosoxidans ATCC 27061 NCTC 10808 Achromobacter xylosoxidans subsp. xylosoxidans ATCC 17062 NCTC 10809 Achromobacter xylosoxidans subsp. xylosoxidans ATCC 27063 NCTC 12156 Acinetobacter baumannii ATCC 19606 NCTC 10303 Acinetobacter baumannii ATCC 17904 NCTC 7844 Acinetobacter calcoaceticus ATCC 15308 NCTC 12983 Acinetobacter calcoaceticus ATCC 23055 NCTC 8102 acinetobacter dna group 13 ATCC 17903 NCTC 10304 Acinetobacter genospecies 13 ATCC 17905 NCTC 10306 Acinetobacter haemolyticus ATCC 17907 NCTC 10305 Acinetobacter haemolyticus subsp haemolyticus ATCC 17906 NCTC 10308 Acinetobacter johnsonii ATCC 17909 NCTC 10307 Acinetobacter junii ATCC 17908 NCTC 5866 Acinetobacter lwoffii ATCC 15309 NCTC 12870 Actinobacillus delphinicola ATCC 700179 NCTC 8529 Actinobacillus equuli ATCC 19392
  • Legionella Shows a Diverse Secondary Metabolism Dependent on a Broad Spectrum Sfp-Type Phosphopantetheinyl Transferase

    Legionella Shows a Diverse Secondary Metabolism Dependent on a Broad Spectrum Sfp-Type Phosphopantetheinyl Transferase

    Legionella shows a diverse secondary metabolism dependent on a broad spectrum Sfp-type phosphopantetheinyl transferase Nicholas J. Tobias1, Tilman Ahrendt1, Ursula Schell2, Melissa Miltenberger1, Hubert Hilbi2,3 and Helge B. Bode1,4 1 Fachbereich Biowissenschaften, Merck Stiftungsprofessur fu¨r Molekulare Biotechnologie, Goethe Universita¨t, Frankfurt am Main, Germany 2 Max von Pettenkofer Institute, Ludwig-Maximilians-Universita¨tMu¨nchen, Munich, Germany 3 Institute of Medical Microbiology, University of Zu¨rich, Zu¨rich, Switzerland 4 Buchmann Institute for Molecular Life Sciences, Goethe Universita¨t, Frankfurt am Main, Germany ABSTRACT Several members of the genus Legionella cause Legionnaires’ disease, a potentially debilitating form of pneumonia. Studies frequently focus on the abundant number of virulence factors present in this genus. However, what is often overlooked is the role of secondary metabolites from Legionella. Following whole genome sequencing, we assembled and annotated the Legionella parisiensis DSM 19216 genome. Together with 14 other members of the Legionella, we performed comparative genomics and analysed the secondary metabolite potential of each strain. We found that Legionella contains a huge variety of biosynthetic gene clusters (BGCs) that are potentially making a significant number of novel natural products with undefined function. Surprisingly, only a single Sfp-like phosphopantetheinyl transferase is found in all Legionella strains analyzed that might be responsible for the activation of all carrier proteins in primary (fatty acid biosynthesis) and secondary metabolism (polyketide and non-ribosomal peptide synthesis). Using conserved active site motifs, we predict Submitted 29 June 2016 some novel compounds that are probably involved in cell-cell communication, Accepted 25 October 2016 Published 24 November 2016 differing to known communication systems.
  • Which Organisms Are Used for Anti-Biofouling Studies

    Which Organisms Are Used for Anti-Biofouling Studies

    Table S1. Semi-systematic review raw data answering: Which organisms are used for anti-biofouling studies? Antifoulant Method Organism(s) Model Bacteria Type of Biofilm Source (Y if mentioned) Detection Method composite membranes E. coli ATCC25922 Y LIVE/DEAD baclight [1] stain S. aureus ATCC255923 composite membranes E. coli ATCC25922 Y colony counting [2] S. aureus RSKK 1009 graphene oxide Saccharomycetes colony counting [3] methyl p-hydroxybenzoate L. monocytogenes [4] potassium sorbate P. putida Y. enterocolitica A. hydrophila composite membranes E. coli Y FESEM [5] (unspecified/unique sample type) S. aureus (unspecified/unique sample type) K. pneumonia ATCC13883 P. aeruginosa BAA-1744 composite membranes E. coli Y SEM [6] (unspecified/unique sample type) S. aureus (unspecified/unique sample type) graphene oxide E. coli ATCC25922 Y colony counting [7] S. aureus ATCC9144 P. aeruginosa ATCCPAO1 composite membranes E. coli Y measuring flux [8] (unspecified/unique sample type) graphene oxide E. coli Y colony counting [9] (unspecified/unique SEM sample type) LIVE/DEAD baclight S. aureus stain (unspecified/unique sample type) modified membrane P. aeruginosa P60 Y DAPI [10] Bacillus sp. G-84 LIVE/DEAD baclight stain bacteriophages E. coli (K12) Y measuring flux [11] ATCC11303-B4 quorum quenching P. aeruginosa KCTC LIVE/DEAD baclight [12] 2513 stain modified membrane E. coli colony counting [13] (unspecified/unique colony counting sample type) measuring flux S. aureus (unspecified/unique sample type) modified membrane E. coli BW26437 Y measuring flux [14] graphene oxide Klebsiella colony counting [15] (unspecified/unique sample type) P. aeruginosa (unspecified/unique sample type) graphene oxide P. aeruginosa measuring flux [16] (unspecified/unique sample type) composite membranes E.
  • Microbial Diversity Under Extreme Euxinia: Mahoney Lake, Canada V

    Microbial Diversity Under Extreme Euxinia: Mahoney Lake, Canada V

    Geobiology (2012), 10, 223–235 DOI: 10.1111/j.1472-4669.2012.00317.x Microbial diversity under extreme euxinia: Mahoney Lake, Canada V. KLEPAC-CERAJ,1,2 C. A. HAYES,3 W. P. GILHOOLY,4 T. W. LYONS,5 R. KOLTER2 AND A. PEARSON3 1Department of Molecular Genetics, Forsyth Institute, Cambridge, MA, USA 2Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA, USA 3Department of Earth and Planetary Sciences, Harvard University, Cambridge, MA, USA 4Department of Earth and Planetary Sciences, Washington University, Saint Louis, MO, USA 5Department of Earth Sciences, University of California, Riverside, CA, USA ABSTRACT Mahoney Lake, British Columbia, Canada, is a stratified, 15-m deep saline lake with a euxinic (anoxic, sulfidic) hypolimnion. A dense plate of phototrophic purple sulfur bacteria is found at the chemocline, but to date the rest of the Mahoney Lake microbial ecosystem has been underexamined. In particular, the microbial community that resides in the aphotic hypolimnion and ⁄ or in the lake sediments is unknown, and it is unclear whether the sulfate reducers that supply sulfide for phototrophy live only within, or also below, the plate. Here we profiled distribu- tions of 16S rRNA genes using gene clone libraries and PhyloChip microarrays. Both approaches suggest that microbial diversity is greatest in the hypolimnion (8 m) and sediments. Diversity is lowest in the photosynthetic plate (7 m). Shallower depths (5 m, 7 m) are rich in Actinobacteria, Alphaproteobacteria, and Gammaproteo- bacteria, while deeper depths (8 m, sediments) are rich in Crenarchaeota, Natronoanaerobium, and Verrucomi- crobia. The heterogeneous distribution of Deltaproteobacteria and Epsilonproteobacteria between 7 and 8 m is consistent with metabolisms involving sulfur intermediates in the chemocline, but complete sulfate reduction in the hypolimnion.
  • Decision Summary

    Decision Summary

    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: K181324 B. Purpose for Submission: To obtain a substantial equivalence determination for the FilmArray Pneumonia Panel plus C. Measurands: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae complex, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae group, Moraxella catarrhalis, Proteus spp., Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, Adenovirus, Coronavirus, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza B, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza Virus, Respiratory Syncytial Virus, CTX-M, IMP, KPC, NDM, OXA-48-like, VIM, mecA/C and MREJ. D. Type of Test: Qualitative and quantitative nucleic acid amplification assay E. Applicant: BioFire Diagnostics, LLC F. Proprietary and Established Names: FilmArray Pneumonia Panel plus G. Regulatory Information: 1. Regulation section: 21 CFR 866.4001 – MERS-CoV and common respiratory pathogens multiplex nucleic acid detection system 2. Classification: Class II (Special Controls) 3. Product code: PZF 4. Panel: 83-Microbiology H. Indications for use: 1. Indications for use(s): The FilmArray Pneumonia Panel plus is a multiplexed nucleic acid test intended for use with FilmArray, FilmArray 2.0, or FilmArray Torch systems for the simultaneous detection and identification of nucleic acids from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria.
  • The Risk to Human Health from Free-Living Amoebae Interaction with Legionella in Drinking and Recycled Water Systems

    The Risk to Human Health from Free-Living Amoebae Interaction with Legionella in Drinking and Recycled Water Systems

    THE RISK TO HUMAN HEALTH FROM FREE-LIVING AMOEBAE INTERACTION WITH LEGIONELLA IN DRINKING AND RECYCLED WATER SYSTEMS Dissertation submitted by JACQUELINE MARIE THOMAS BACHELOR OF SCIENCE (HONOURS) AND BACHELOR OF ARTS, UNSW In partial fulfillment of the requirements for the award of DOCTOR OF PHILOSOPHY in ENVIRONMENTAL ENGINEERING SCHOOL OF CIVIL AND ENVIRONMENTAL ENGINEERING FACULTY OF ENGINEERING MAY 2012 SUPERVISORS Professor Nicholas Ashbolt Office of Research and Development United States Environmental Protection Agency Cincinnati, Ohio USA and School of Civil and Environmental Engineering Faculty of Engineering The University of New South Wales Sydney, Australia Professor Richard Stuetz School of Civil and Environmental Engineering Faculty of Engineering The University of New South Wales Sydney, Australia Doctor Torsten Thomas School of Biotechnology and Biomolecular Sciences Faculty of Science The University of New South Wales Sydney, Australia ORIGINALITY STATEMENT '1 hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom 1 have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.' Signed ~ ............................
  • Potential Role of Microbiome in Oncogenesis, Outcome Prediction

    Potential Role of Microbiome in Oncogenesis, Outcome Prediction

    Oral Oncology 99 (2019) 104453 Contents lists available at ScienceDirect Oral Oncology journal homepage: www.elsevier.com/locate/oraloncology Review Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer T ⁎ Ester Orlandia,b, , Nicola Alessandro Iacovellib, Vincenzo Tombolinic, Tiziana Rancatid, Antonella Polimenie, Loris De Ceccof, Riccardo Valdagnia,d,g, Francesca De Felicec a Department of Radiotherapy 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy b Department of Radiotherapy 2, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy c Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy d Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy e Department of Oral and Maxillo Facial Sciences, Policlinico Umberto I, “Sapienza” University of Rome, Italy f Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy g Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy ARTICLE INFO ABSTRACT Keywords: In the last decade, human microbiome research is rapidly growing involving several fields of clinical medicine Head and neck cancer and population health. Although the microbiome seems to be linked to all sorts of diseases, cancer has the Biomarkers biggest potential to be investigated. Microbiome Following the publication of the National Institute of Health - Human Microbiome Project (NIH-HMP), the Microbiota link between Head and Neck Cancer (HNC) and microbiome seems to be a fast-moving field in research area. Oncogenesis However, robust evidence-based literature is still quite scarce. Nevertheless the relationship between oral mi- Radiotherapy Immunotherapy crobiome and HNC could have important consequences for prevention and early detection of this type of tumors.
  • 3. Jedna Z Krvných Skupín Systému AB0; 4. Skr. Bukálny. B – Symbo

    3. Jedna Z Krvných Skupín Systému AB0; 4. Skr. Bukálny. B – Symbo

    B – 1. symbol pre bel; 2. chem. značka prvku →bór; 3. jedna z krvných skupín systému AB0; 4. skr. bukálny. B – symbol pre hustotu magnetického toku. B. – skr. pre →Bacillus. B-ALP – skr. angl. bone alcalic phosphatase kostná alkalická fosfatáza. B-bunky – 1. syn. -bunky Langerhansových ostrovčekov; →pankreas; 2. syn. B-lymfocyty; →lymfocyty. B-komplex – multivitamínový prípravok vitamínov B. B-lymfocyty – [B podľa Fabriciovej burzy, imunol. orgánu vtákov] B bunky, druh lymfocytov, kt. sa zúčastňuje na humorálnej imunite (tvorbe protilátok) a niekt. ďalších imunitných funkciách. Povrchové molekuly sú CD 19,20. Receptorom pre antigén je membránový imunoglobulín. B-reťazec – jeden z polypeptidových reťazcov →inzulínu. B-vírus – 1. vírus →hepatitídy B.; 2. vírus zo skupiny Cercopithecine herpes virus 1. B-vlákna →nerv. b – skr. 1. pre barn; 2. skr. angl. born narodený; 3. skr. báza (genet. označenie dĺţky sekvencie nukleotidov, napr. 50 b = sekvencia 50 nukleotidov). b-vlna – pozit. kmit s vyskou amplitúdou v →elektroretinograme nasledujúci po vlne a, prejav komplexnej aktivity vrstvy bipolárnych buniek. – - – predpona označujúca 1. staršie označenie druhého atómu uhlíka v reťazci, na kt. sa pripája hlavná funkčná skupina, napr. kys. -hydroxymaslová správ. kys. 3-hydroxymaslová; 2. špecifická rotácia opticky aktívnej látky, napr. -D-glukóza; 3. orientácia exocyklického atómu al. skupiny, napr. cholest-5-en-3--ol; 4. plazmatický proteín, kt. migruje v elektroforéze v pruhu - lipoproteín; 5. člen série príbuzných chem. látok, najmä série stereoizomérov, izomérov, polymérov al. alotroických foriem, napr. -karotén; 6. -lúč. B2 – staršie označenie pre CD21. B4 – staršie označenie pre CD 19. B19 virus – ľudský parvovírus z čeľade Parvoviridae, značne rozšírený, vyvolávajúci obvykle inaparentné infekcie.
  • 974-Form.Pdf

    974-Form.Pdf

    California Association for Medical Laboratory Technology Distance Learning Program ANAEROBIC BACTERIOLOGY FOR THE CLINICAL LABORATORY by James I. Mangels, MA, CLS, MT(ASCP) Consultant Microbiology Consulting Services Santa Rosa, CA Course Number: DL-974 3.0 CE/Contact Hour Level of Difficulty: Intermediate © California Association for Medical Laboratory Technology. Permission to reprint any part of these materials, other than for credit from CAMLT, must be obtained in writing from the CAMLT Executive Office. CAMLT is approved by the California Department of Health Services as a CA CLS Accrediting Agency (#0021) and this course is is approved by ASCLS for the P.A.C.E. ® Program (#519) 1895 Mowry Ave, Suite 112 Fremont, CA 94538-1766 Phone: 510-792-4441 FAX: 510-792-3045 Notification of Distance Learning Deadline All continuing education units required to renew your license must be earned no later than the expiration date printed on your license. If some of your units are made up of Distance Learning courses, please allow yourself enough time to retake the test in the event you do not pass on the first attempt. CAMLT urges you to earn your CE units early!. CAMLT Distance Learning Course # DL-974 1 © California Association for Medical Laboratory Technology Outline A. Introduction B. What are anaerobic bacteria? Concepts of anaerobic bacteriology C. Why do we need to identify anaerobes? D. Normal indigenous anaerobic flora; the incidence of anaerobes at various body sites E. Anaerobic infections; most common anaerobic infections F. Specimen collection and transport; acceptance and rejection criteria G. Processing of clinical specimens 1. Microscopic examination 2.
  • List of the Pathogens Intended to Be Controlled Under Section 18 B.E

    List of the Pathogens Intended to Be Controlled Under Section 18 B.E

    (Unofficial Translation) NOTIFICATION OF THE MINISTRY OF PUBLIC HEALTH RE: LIST OF THE PATHOGENS INTENDED TO BE CONTROLLED UNDER SECTION 18 B.E. 2561 (2018) By virtue of the provision pursuant to Section 5 paragraph one, Section 6 (1) and Section 18 of Pathogens and Animal Toxins Act, B.E. 2558 (2015), the Minister of Public Health, with the advice of the Pathogens and Animal Toxins Committee, has therefore issued this notification as follows: Clause 1 This notification is called “Notification of the Ministry of Public Health Re: list of the pathogens intended to be controlled under Section 18, B.E. 2561 (2018).” Clause 2 This Notification shall come into force as from the following date of its publication in the Government Gazette. Clause 3 The Notification of Ministry of Public Health Re: list of the pathogens intended to be controlled under Section 18, B.E. 2560 (2017) shall be cancelled. Clause 4 Define the pathogens codes and such codes shall have the following sequences: (1) English alphabets that used for indicating the type of pathogens are as follows: B stands for Bacteria F stands for fungus V stands for Virus P stands for Parasites T stands for Biological substances that are not Prion R stands for Prion (2) Pathogen risk group (3) Number indicating the sequence of each type of pathogens Clause 5 Pathogens intended to be controlled under Section 18, shall proceed as follows: (1) In the case of being the pathogens that are utilized and subjected to other law, such law shall be complied. (2) Apart from (1), the law on pathogens and animal toxin shall be complied.
  • Genetic and Functional Studies of the Mip Protein of Legionella

    Genetic and Functional Studies of the Mip Protein of Legionella

    t1.ì. Genetic and Functional Studies of the Mip Protein of Legionella Rodney Mark Ratcliff, BSc (Hons)' MASM Infectious Diseases Laboratories Institute of Medical and Veterinary Science and Department of Microbiology and Immunology UniversitY of Adelaide. Adelaide, South Australia A thesis submitted to the University of Adelaide for the degree of I)octor of Philosophy 15'h March 2000 amended 14th June 2000 Colonies of several Legionella strains on charcoal yeast extract agar (CYE) after 4 days incubation at 37"C in air. Various magnifications show typical ground-glass opalescent appearance. Some pure strains exhibit pleomorphic growth or colour. The top two photographs demonstrate typical red (LH) and blue-white (RH) fluorescence exhibited by some species when illuminated by a Woods (IJV) Lamp. * t Table of Contents .1 Chapter One: Introduction .1 Background .............'. .2 Morphology and TaxonomY J Legionellosis ............. 5 Mode of transmission "..'....'. 7 Environmental habitat 8 Interactions between Legionella and phagocytic hosts 9 Attachment 11 Engulfment and internalisation.'.. 13 Intracellular processing 13 Intracellular replication of legionellae .. " "' " "' 15 Host cell death and bacterial release 18 Virulence (the Genetic factors involved with intracellular multiplication and host cell killing .20 icm/dot system) Legiolysin .25 Msp (Znn* metaloprotease) ...'..... .25 .28 Lipopolysaccharide .29 The association of flagella with disease.. .30 Type IV fimbriae.... .31 Major outer membrane proteins....'.......'. JJ Heat shock proteins'.'. .34 Macrophage infectivity potentiator (Mip) protein Virulenceiraits of Legionella species other than L. pneumophila..........' .39 phylogeny .41 Chapter One (continued): Introduction to bacterial classification and .41 Identificati on of Legionella...'.,..'.. .46 Phylogeny .52 Methods of phylogenetic analysis' .53 Parsimony methods.'.. .55 Distance methods UPGMA cluster analYsis.'.'...
  • Electronic Laboratory Reporting Use Case January 2011

    Electronic Laboratory Reporting Use Case January 2011

    ILLINOIS HEALTH INFORMATION EXCHANGE Electronic Laboratory Reporting Use Case Electronic Laboratory Reporting and Health Information Exchange Illinois Health Information Exchange Public Health Work Group January 2011 Electronic Laboratory Reporting Use Case January 2011 Table of Contents 1.0 Executive Summary……………………………………………………………………….3 2.0 Introduction…………………………………………………………………...……………..5 3.0 Scope……………………………………..………………………………………………………5 4.0 Use Case Stakeholders…………………………………………………………….….....6 5.0 Issues and Obstacles……………………………………………………………………...8 6.0 Use Case Pre-Conditions .………………….…………………………………………...8 7.0 Use Case Post-Conditions.……………………………………………………………...9 8.0 Detailed Scenarios/Technical Specifications.………………………………10 9.0 Validation and Certification………………………………………………………...12 Appendix ………………………………………………………………………………………….....13 Page 2 Electronic Laboratory Reporting Use Case January 2011 1.0 Executive Summary This Use Case is a product of the Public Health Work Group (PHWG) of the Illinois Health Information Exchange (HIE) Advisory Committee. The Illinois HIE Advisory Committee was constituted as the diverse public healthcare stakeholder body providing input and recommendations on the creation of the Illinois Health Information Exchange Authority (“the Authority”) as the Illinois vehicle for designing and implementing electronic health information exchange in Illinois. The establishment of the Authority marks the formal transition of the work of the HIE Advisory Committee and the Work Groups into alignment with the provisions of Illinois